Document Detail


Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy.
MedLine Citation:
PMID:  14691120     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: To determine if obesity is associated with higher prostate specific antigen recurrence rates after radical prostatectomy (RP), and to explore racial differences in body mass index (BMI) as a potential explanation for the disparity in outcome between black and white men. PATIENTS AND METHODS: A retrospective, multi-institutional pooled analysis of 3,162 men undergoing RP was conducted at nine US military medical centers between 1987 and 2002. Patients were initially categorized as obese (BMI > or = 30 kg/m(2)), overweight (BMI 25 to 30 kg/m(2)), or normal (BMI < or = 25 kg/m(2)). For analysis, normal and overweight groups were combined (BMI < 30 kg/m(2)) and compared with the obese group (BMI > or = 30 kg/m(2)) with regard to biochemical recurrence (prostate-specific antigen > or = 0.2 ng/mL) after RP. RESULTS: Of 3,162 patients, 600 (19.0%) were obese and 2,562 (81%) were not obese. BMI was an independent predictor of higher Gleason grade cancer (P <.001) and was associated with a higher risk of biochemical recurrence (P =.027). Blacks had higher BMI (P <.001) and higher recurrence rates (P =.003) than whites. Both BMI (P =.028) and black race (P =.002) predicted higher prostate specific antigen recurrence rates. In multivariate analysis of race, BMI, and pathologic factors, black race (P =.021) remained a significant independent predictor of recurrence. CONCLUSION: Obesity is associated with higher grade cancer and higher recurrence rates after RP. Black men have higher recurrence rates and greater BMI than white men. These findings support the hypothesis that obesity is associated with progression of latent to clinically significant prostate cancer (PC) and suggest that BMI may account, in part, for the racial variability in PC risk.
Authors:
Christopher L Amling; Robert H Riffenburgh; Leon Sun; Judd W Moul; Raymond S Lance; Leo Kusuda; Wade J Sexton; Douglas W Soderdahl; Timothy F Donahue; John P Foley; Andrew K Chung; David G McLeod
Publication Detail:
Type:  Journal Article; Multicenter Study; Research Support, U.S. Gov't, Non-P.H.S.     Date:  2003-12-22
Journal Detail:
Title:  Journal of clinical oncology : official journal of the American Society of Clinical Oncology     Volume:  22     ISSN:  0732-183X     ISO Abbreviation:  J. Clin. Oncol.     Publication Date:  2004 Feb 
Date Detail:
Created Date:  2004-01-30     Completed Date:  2004-02-24     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8309333     Medline TA:  J Clin Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  439-45     Citation Subset:  IM    
Affiliation:
Department of Urology, Naval Medical Center, 34800 Bob Wilson Drive, San Diego, CA 92134-5000, USA. clamling@nmcsd.med.navy.mil
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
African Continental Ancestry Group*
Body Mass Index
European Continental Ancestry Group*
Humans
Male
Military Personnel
Neoplasm Recurrence, Local / blood,  ethnology*,  etiology
Neoplasm Staging
Obesity / complications,  ethnology*
Prognosis
Prostate-Specific Antigen / blood
Prostatectomy*
Prostatic Neoplasms / ethnology*,  etiology,  surgery
Retrospective Studies
Risk Factors
United States
Chemical
Reg. No./Substance:
EC 3.4.21.77/Prostate-Specific Antigen
Comments/Corrections
Comment In:
J Clin Oncol. 2005 Apr 1;23(10):2434-5; author reply 2435   [PMID:  15800342 ]
J Clin Oncol. 2004 Feb 1;22(3):395-8   [PMID:  14691129 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Study on the organoleptic intensity scale for measuring oral malodor.
Next Document:  Are patients diagnosed with breast cancer before age 50 years ever cured?